Last reviewed · How we verify
Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers
Approved treatments
- Rinvoq · AbbVie Inc.
JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers patent landscape — cliff calendar, originator estates, attackable patents
- Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers treatment landscape brief
- Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers treatment updates RSS
Frequently asked questions about Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers
What drugs treat Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers?
Tracked treatments include Rinvoq.
What is the treatment for Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers?
Standard treatment for Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers includes Rinvoq. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers patent cliff · Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers CI report
- Treatment: Rinvoq · AbbVie Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing